Business
Narcolepsy Market is Projected to Grow at a CAGR of 5.6% During the Forecast Period (2025-2034) Due to Increasing Disease Awareness, Improved Diagnosis, and Expanding Therapeutic Options | DelveInsight
DelveInsight's Narcolepsy Market Insights report includes a comprehensive understanding of current treatment practices, narcolepsy emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"text","content":"The narcolepsy market landscape is evolving from symptomatic management toward targeted, mechanism-based approaches that address the underlying neurochemical dysregulation of the orexin system. New drug classes targeting the orexin and monoaminergic systems are redefining narcolepsy treatment. Orexin agonists such as Oreporexton (Takeda), along with next-generation agents like Reboxetine (Axsome Therapeutics) and Quilience (NLS Pharmaceutics), aim to restore wakefulness regulation at its neurobiological root.","length":514,"tagName":"p"},{"type":"text","content":"LAS VEGAS, Dec. 2, 2025 /PRNewswire/ -- DelveInsight's Narcolepsy Market Insights report includes a comprehensive understanding of current treatment practices, narcolepsy emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].","length":424,"tagName":"p"},{"type":"image","alt":"DelveInsight Logo","displaySize":"","headline":null,"caption":"DelveInsight Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":181,"url":"https://media.zenfs.com/en/prnewswire.com/9711e6be91b3534a074e21a35fd57d95"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Eyi6JBwtj.guENW.piLYXg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMxOTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/9711e6be91b3534a074e21a35fd57d95","width":400,"height":181}}},{"type":"text","content":"Narcolepsy Market Summary","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The market size for narcolepsy was found to be USD 2.5 billion in the leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] in 2024.","length":195,"tagName":"p"}]},{"val":[{"type":"text","content":"The United States accounted for the largest narcolepsy treatment market size, approximately 80% of the total market size in the 7MM in 2024, compared to other major markets, including the EU4 countries, the United Kingdom, and Japan.","length":233,"tagName":"p"}]},{"val":[{"type":"text","content":"In 2024, DelveInsight estimated around 360,000 diagnosed prevalent cases of narcolepsy across the 7MM, underscoring its significant clinical ...